| Title: | Toward precision medicine : molecular biomarkers of response to tofacitinib in inflammatory bowel disease |
|---|
| Authors: | ID Bizjak, Anja (Author)
ID Gole, Boris (Author)
ID Jezernik, Gregor (Author)
ID Potočnik, Uroš (Author)
ID Gorenjak, Mario (Author) |
|---|
| Files: |  RAZ_Bizjak_Anja_2025.pdf (881,71 KB)
MD5: 42723389EB621E8FF49168B05CD88085
 https://doi.org/10.3390/genes16080908
https://www.mdpi.com/2073-4425/16/8/908
|
|---|
| Language: | English |
|---|
| Work type: | Scientific work |
|---|
| Typology: | 1.02 - Review Article |
|---|
| Organization: | MF - Faculty of Medicine
|
|---|
| Abstract: | Ulcerative colitis (UC), a subtype of inflammatory bowel disease (IBD), is a chronic, relapsing inflammatory condition that significantly impairs the patient’s quality of life. While biologics have transformed disease management, a substantial number of patients remain unresponsive or lose efficacy over time. Tofacitinib (TOFA), an oral Janus kinase (JAK) inhibitor, introduces a novel therapeutic class of small-molecule drugs with a unique oral administration route, offering enhanced patient convenience and broader accessibility compared to parenterally administered biologics. As the first oral treatment approved for moderate to severe UC in years, TOFA acts by modulating the JAK/STAT pathway, influencing critical inflammatory mediators such as IL-6, IL-17, and IFN-γ. However, response rates are variable and appear dose-dependent, with up to 60% of patients showing inadequate therapeutic outcomes. This review represents the first comprehensive synthesis focused specifically on biomarkers of TOFA response in UC. Drawing on multi-omics data—epigenomics, transcriptomics, proteomics, and cellular profiling, we highlight emerging predictors of responsiveness, including CpG methylation signatures (e.g., LRPAP1 and FGFR2), transcriptomic regulators (e.g., REG3A and CLDN3), immune and epithelial cell shifts, and the cationic transporter MATE1. TOFA demonstrates a dual mechanism by modulating immune responses while supporting epithelial barrier restoration. Despite being promising, TOFA’s dose-dependent efficacy and interpatient variability underscore the critical need for non-invasive, predictive biomarkers to guide personalized treatment. As the first review of its kind, this work establishes a basis for precision medicine approaches to optimize the clinical utility of TOFA in UC management. |
|---|
| Keywords: | inflammatory bowel disease, ulcerative colitis, genomics, tofacitinib, transcriptomics, proteomics |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Submitted for review: | 27.07.2025 |
|---|
| Article acceptance date: | 10.07.2025 |
|---|
| Publication date: | 29.07.2025 |
|---|
| Publisher: | MDPI |
|---|
| Year of publishing: | 2025 |
|---|
| Number of pages: | Str. [1]-23 |
|---|
| Numbering: | Letn. 16, Št. 8 |
|---|
| PID: | 20.500.12556/DKUM-94341  |
|---|
| UDC: | 616.34-002 |
|---|
| ISSN on article: | 2073-4425 |
|---|
| COBISS.SI-ID: | 245399043 |
|---|
| DOI: | 10.3390/genes16080908 |
|---|
| Publication date in DKUM: | 18.08.2025 |
|---|
| Views: | 295 |
|---|
| Downloads: | 19 |
|---|
| Metadata: |    |
|---|
| Categories: | Misc.
|
|---|
|
:
|
Copy citation |
|---|
| | | | Average score: | (0 votes) |
|---|
| Your score: | Voting is allowed only for logged in users. |
|---|
| Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
